000290171 001__ 290171
000290171 005__ 20250731112116.0
000290171 0247_ $$2doi$$a10.1002/ijc.34951
000290171 0247_ $$2pmid$$apmid:38733362
000290171 0247_ $$2ISSN$$a0020-7136
000290171 0247_ $$2ISSN$$a1097-0215
000290171 0247_ $$2altmetric$$aaltmetric:163322934
000290171 037__ $$aDKFZ-2024-01007
000290171 041__ $$aEnglish
000290171 082__ $$a610
000290171 1001_ $$00000-0003-2667-3927$$aRostami, Sina$$b0
000290171 245__ $$aDifferential levels of circulating RNAs prior to endometrial cancer diagnosis.
000290171 260__ $$aBognor Regis$$bWiley-Liss$$c2024
000290171 3367_ $$2DRIVER$$aarticle
000290171 3367_ $$2DataCite$$aOutput Types/Journal article
000290171 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1720427211_6945
000290171 3367_ $$2BibTeX$$aARTICLE
000290171 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290171 3367_ $$00$$2EndNote$$aJournal Article
000290171 500__ $$a2024 Sep 1;155(5):946-956
000290171 520__ $$aEndometrial cancer (EC) is one of the most common female cancers and there is currently no routine screening strategy for early detection. An altered abundance of circulating microRNAs (miRNAs) and other RNA classes have the potential as early cancer biomarkers. We analyzed circulating RNA levels using small RNA sequencing, targeting RNAs in the size range of 17-47 nucleotides, in EC patients with samples collected prior to diagnosis compared to cancer-free controls. The analysis included 316 cases with samples collected 1-11 years prior to EC diagnosis, and 316 matched controls, both from the Janus Serum Bank cohort in Norway. We identified differentially abundant (DA) miRNAs, isomiRs, and small nuclear RNAs between EC cases and controls. The top EC DA miRNAs were miR-155-5p, miR-200b-3p, miR-589-5p, miR-151a-5p, miR-543, miR-485-5p, miR-625-p, and miR-671-3p. miR-200b-3p was previously reported to be among one of the top miRNAs with higher abundance in EC cases. We observed 47, 41, and 32 DA miRNAs for EC interacting with BMI, smoking status, and physical activity, respectively, including two miRNAs (miR-223-3p and miR-29b-3p) interacting with all three factors. The circulating RNAs are altered and show temporal dynamics prior to EC diagnosis. Notably, DA miRNAs for EC had the lowest q-value 4.39-6.66 years before diagnosis. Enrichment analysis of miRNAs showed that signaling pathways Fc epsilon RI, prolactin, toll-like receptor, and VEGF had the strongest associations.
000290171 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000290171 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290171 650_7 $$2Other$$aRNA
000290171 650_7 $$2Other$$aRNA‐sequencing
000290171 650_7 $$2Other$$acell‐free nucleic acids
000290171 650_7 $$2Other$$aendometrial neoplasms
000290171 7001_ $$00000-0003-2677-2722$$aRounge, Trine B$$b1
000290171 7001_ $$aPestarino, Luca$$b2
000290171 7001_ $$aLyle, Robert$$b3
000290171 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée Turzanski$$b4$$udkfz
000290171 7001_ $$00000-0001-5288-7879$$aHaaland, Øystein Ariansen$$b5
000290171 7001_ $$aLie, Rolv T$$b6
000290171 7001_ $$00000-0002-4623-0544$$aWiklund, Fredrik$$b7
000290171 7001_ $$00000-0002-9096-5257$$aBjørge, Tone$$b8
000290171 7001_ $$00000-0002-9446-4855$$aLangseth, Hilde$$b9
000290171 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34951$$gp. ijc.34951$$n5$$p946-956$$tInternational journal of cancer$$v155$$x0020-7136$$y2024
000290171 8564_ $$uhttps://inrepo02.dkfz.de/record/290171/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Rostami%20-%20Differential%20levels%20of%20circulating%20RNAs%20prior%20to%20endometrial%20cancer%20diagnosis.pdf
000290171 8564_ $$uhttps://inrepo02.dkfz.de/record/290171/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Rostami%20-%20Differential%20levels%20of%20circulating%20RNAs%20prior%20to%20endometrial%20cancer%20diagnosis.pdf?subformat=pdfa$$xpdfa
000290171 909CO $$ooai:inrepo02.dkfz.de:290171$$pVDB
000290171 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000290171 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000290171 9141_ $$y2024
000290171 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000290171 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000290171 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000290171 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000290171 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000290171 980__ $$ajournal
000290171 980__ $$aVDB
000290171 980__ $$aI:(DE-He78)C020-20160331
000290171 980__ $$aUNRESTRICTED